Veracyte (VCYT) Other Operating Expenses (2012 - 2026)

Veracyte has disclosed Other Operating Expenses across 15 years of filings, most recently posting $27.7 million for Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $27.7 million, up 10.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $125.8 million (up 23.08% YoY), and the FY2025 annual result was $123.2 million, up 20.63% from the prior year.
• Other Operating Expenses came in at $27.7 million for Q1 2026 at Veracyte, up from $26.6 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $59.8 million in Q3 2023 to a low of -$64.6 million in Q4 2022.
• The 5-year median for Other Operating Expenses is $27.7 million (2026), against an average of $32.7 million.
• Across the five-year window, Other Operating Expenses tumbled 227.81% in 2022 and jumped 189.47% in 2023, its largest moves.
• Veracyte's Other Operating Expenses stood at -$64.6 million in 2022, then surged by 189.47% to $57.8 million in 2023, then plunged by 50.93% to $28.4 million in 2024, then decreased by 6.39% to $26.6 million in 2025, then increased by 4.42% to $27.7 million in 2026.
• The last three Other Operating Expenses figures came in at $27.7 million (Q1 2026), $26.6 million (Q4 2025), and $25.1 million (Q3 2025), per Business Quant data.